What Mabylon does

Mabylon AG is a clinical-stage Swiss biotechnology company founded in 2015 as a spinout from ImmunoQure and headquartered in Schlieren, Zürich. It discovers and engineers novel antibody therapeutics in three therapeutic areas: severe allergies (food and pollen), inflammatory diseases (notably inflammatory bowel disease and neuroinflammation), and neurology (ALS and frontotemporal dementia). Its lead asset, MY006, is a trispecific anti-peanut antibody currently in Phase I clinical development (Phase Ia completed with favorable safety and pharmacokinetic profiles, Phase Ib initiated as of May 2026), offering a prophylactic passive-immunization approach with only a few subcutaneous injections per year.

The company's core technology is a proprietary human-derived antibody discovery platform that combines single-cell B-cell screening with high-throughput antibody-expression workflows to identify and clone natural B-cell-derived monoclonal antibodies within two to three weeks, followed by functional assays and engineering to produce multispecific therapeutics such as the trispecific MY006. Its broader pipeline includes MY010 (multispecific antibody against birch and related tree/fruit/nut allergens, preclinical), MY011 (cross-reactive grass pollen antibody, preclinical), MY001 (TDP-43 intrabody for ALS/FTD, preclinical), and MY012 (anti-ASC inflammasome antibody for IBD/neuroinflammation, preclinical). The platform is supported by Clinical Development Advisory Boards in food and pollen allergies drawing on clinicians and researchers from institutions including Mass General, Harvard, University of Bonn, and Novartis.

Mabylon is pre-revenue and pursues an enterprise partnership and licensing model rather than direct commercialization. Strategic relationships include Pfizer (via Pfizer Ignite for CMC and IND-enabling work on MY006), SciNeuro Pharmaceuticals (collaboration and license agreement for ALS/FTLD antibody therapeutics), and a broad base of academic and grant partners (Innosuisse, Target ALS, ALS Association, NIH, EU Horizon 2020, Eurostars). Capital is sourced primarily from private investors, with a CHF 30 million round closed in August 2025 led by former Roche management and board members to advance MY006 through Phase Ia/b and expand discovery and preclinical programs.

Name

Mabylon

Legal name

Mabylon AG

Website

https://mabylon.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Mabylon AG is a clinical-stage Swiss biotechnology company that discovers and develops human-derived, multispecific antibody therapeutics for severe allergies, inflammatory bowel disease, and neurodegenerative disorders including ALS, using a proprietary single-cell B-cell screening platform.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Antibody therapeutics
• Biopharmaceuticals development
• Allergy immunotherapy
• Human-derived antibodies
• Multi-specific antibodies

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Therapeutic antibody development and licensing: Pre-revenue clinical-stage biotechnology company developing antibody therapeutics for allergies, inflammation, and neurology with pipeline programs in clinical and preclinical stages. Revenue expected through licensing deals, co-development partnerships, and eventual product commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Mabylon AG is a clinical-stage biotechnology company that discovers and engineers novel antibody therapeutics for allergies, inflammation, and neurological disorders. The company leverages a proprietary human-derived antibody discovery platform using B-cell screening and high-throughput expression to identify and clone monoclonal antibodies within two to three weeks, and develops these into multi-specific therapeutic candidates (MY006, MY010, MY011, MY001, MY012). The company advances candidates through clinical development in collaboration with pharmaceutical partners.

Product overview

Mabylon AG is a clinical-stage biotechnology company with an antibody discovery technology platform that leverages human-derived antibodies from patients' immune repertoires to develop multi-specific therapeutics. The company's pipeline consists of multiple antibody programs: MY006 (tri-specific anti-peanut antibody in Phase I for peanut allergy), MY010 (birch pollen antibody in pre-clinical), MY011 (grass pollen antibody in pre-clinical), MY001 (TDP-43 intrabody for ALS in pre-clinical), and MY012 (anti-ASC antibody for IBD/neuroinflammation in pre-clinical). The technology platform enables rapid identification and cloning of B-cell-derived antibodies for development into monoclonal or multi-specific antibody therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• MY006 A tri-specific antibody for the prophylactic treatment of peanut allergy that binds critical allergenic epitopes to neutralize major peanut allergens and prevent anaphylaxis, designed to provide protection with only a few subcutaneous injections per year. Currently in Phase I clinical trials (Phase Ia completed with favorable safety and pharmacokinetic profiles; Phase Ib initiated).
• MY010 A multispecific and cross-reactive antibody targeting the birch pollen allergen Bet v 1 as well as major birch-related tree, fruit and nut allergens, designed to provide superior protection with only one injection pre-season. Currently in pre-clinical development entering CMC and IND-enabling studies.
• MY011 A broadly cross-reactive antibody-based therapeutic designed to neutralize major grass pollen allergens from timothy, rye, and velvet grass, providing rapid and durable protection throughout the season after single administration. Currently advancing through pre-clinical development.
• MY001 Human-derived TDP-43 intrabodies designed to restore normal TDP-43 function by reducing pathological TDP-43 aggregates in diseased neurons, aiming to halt disease progression in amyotrophic lateral sclerosis (ALS). Currently at pre-clinical stages.
• MY012 An anti-ASC antibody targeting ASC, a crucial component of the inflammasome expressed by innate immune cells, to inhibit the propagation of inflammation triggered by ASC specks. Potential applications in inflammatory bowel disease (IBD) and neuroinflammation. Currently at pre-clinical stages.

Quantifiable outcome

• MY006 Phase Ia completed with favorable safety and pharmacokinetic profiles; Safety Monitoring Committee recommended Phase Ib initiation
• +1 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• SciNeuro PharmaceuticalscoreStrategic or Co-development Partner · 26 October 2021SciNeuro and Mabylon announced a Collaboration and License Agreement for the development of immunotherapy to fight ALS and FTLD (frontotemporal dementia), combining Mabylon's antibody expertise with SciNeuro's neurological disease focus.
• Pfizer (Pfizer Ignite)coreStrategic or Co-development PartnerFor CMC and IND-enabling studies of the lead program MY006, Mabylon has collaborated with Pfizer through the Pfizer Ignite offering, an end-to-end service for selected biotech companies. This allowed Mabylon to leverage Pfizer's extensive therapeutic development expertise to speed the progression of the peanut allergy program.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Numab Therapeutics: Swiss privately held biotech developing multi-specific antibody therapeutics; highly comparable as a fellow Schlieren/Zürich-area multi-specific antibody company whose lead asset (NM26) was acquired by J&J for $1.25B in 2024 — Mabylon's CMO Peter Lichtlen co-founded Numab.

Broad incumbents

• Argenx: Late-stage immunology biotech developing antibody therapeutics for autoimmune diseases (e.g., VYVGART); comparable as a clinically validated antibody-focused immunology company and potential future competitor in allergy/inflammation.
• UCB Pharma: Global biopharma with a major focus on immunology/autoimmune and neurology antibody therapeutics; Mabylon's CSO Niccolò Pengo previously worked on antibody therapeutics discovery at UCB.
• Genentech (Roche): Global leader in monoclonal antibody therapeutics and immunology; highly relevant comparator given Mabylon's deep Roche DNA (Chairman Keller and Board member Haenggi are former Roche executives, and investors include former Roche management).
• Vir Biotechnology: Clinical-stage immunology company leveraging human-derived antibody platforms (acquired HUMABS BioMed, Mabylon CEO's former company); comparable for its antibody platform approach and immunology focus, but operates at much larger scale.
• Regeneron Pharmaceuticals: Large-cap biopharma with deep antibody discovery capabilities (VelocImmune platform) and marketed immunology assets (Dupixent); a relevant incumbent comparator for antibody platform reach and commercial scale in immunology.

Emerging players

• BioInvent International: Swedish clinical-stage antibody biotech with a proprietary discovery platform targeting immuno-oncology and autoimmune diseases; comparable as an emerging clinical-stage antibody platform player, and Board member Thomas Hecht sits on BioInvent's board.
• IgGenix: Clinical-stage biotech developing engineered allergen-specific IgG antibodies for food allergies; directly comparable as a passive-immunization antibody competitor in the peanut/food allergy space where Mabylon's MY006 is positioned.
• MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing Nanobody® therapeutics for inflammatory diseases (e.g., hidradenitis suppurativa, psoriatic arthritis); comparable as a publicly listed emerging immunology-focused antibody developer.
• Aiolos Bio: Clinical-stage biotech developing antibody therapeutics for respiratory and inflammatory diseases (formerly focused on severe asthma); comparable as an emerging antibody player in the I&I space.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mabylon

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabylon